ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes

Abstract

The Precision Medicine in Diabetes Initiative (PMDI) was launched in 2018 by the American Diabetes Association (ADA) in collaboration with the European Association for the Study of Diabetes (EASD). The PMDI has subsequently partnered with other organizations including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), JDRF, and the Diabetes Technology Society. The mandate of the PMDI is to establish consensus on the viability and ultimate clinical implementation of precision medicine for the diagnosis, prevention, treatment, prognosis, and monitoring of diabetes. This process is designed to take place through systematic evaluation of available scientific evidence, expert consultation, and broad stakeholder engagement (Fig. 1). The mandate of the PMDI is pursued with the overarching goal of facilitating longer, healthier lives for people living with diabetes, identifying those at risk, and preventing diabetes through multiple interventional approaches.The PMDI held its first international scientific conference in Madrid, Spain, in October 2019. Approximately 100 delegates participated, with attendees from North America, Europe, the Middle East, Asia, and Africa, with diverse representation (including academia, industry, funders, and people with diabetes). The conference provided the foundation and framework from which a first Consensus Report on precision medicine in diabetes was developed and published in 2020 (1). The Consensus Report named five key pillars, or domains, of precision diabetes medicine: precision diagnostics, precision prevention, precision treatment, precision prognostics, and precision monitoring. Across each domain, the article also identified critical gaps in knowledge and evidence required for the scientific advancement, implementation, and ongoing evaluation of precision medicine in diabetes. Newly formed PMDI working groups (composed of 175 internationally leading clinicians and researchers in precision diabetes medicine [Supplementary Appendix]) have since initiated multiple, ongoing evidence-based evaluations in diabetes related to the five key domains.The second international scientific conference organized by the PMDI was held in April 2021 (www.pdm2021.org). This meeting, hosted virtually owing to the coronavirus disease 2019 (COVID-19) pandemic, included more than 3,000 participants from 67 countries. Building on the foundation and framework established at the first conference, diverse stakeholders in the development and implementation of precision diabetes medicine exchanged new data, ideas, and opinions. Over 3 days, the meeting delivered interactive state-of-the-science overviews of all key domains of precision diabetes medicine in research and practice. The PMDI working groups undertaking systematic reviews provided progress updates and summaries of existing evidence and identified critical gaps in current scientific knowledge. Plenary presentations discussed the interface of precision medicine in diabetes with the social determinants of health and dispa...

Artificial Intelligence Methodologies Applied to Technologies for Screening, Diagnosis and Care of the Diabetic Foot: A Narrative Review

“…Of note, in our opinion, despite some pitfalls (as discussed above), neural networks may be a very valuable option among all those available in the artificial intelligence context, for the neural networks ability to “learn” and hence possibly optimize the diabetic foot strategy for different categories of diabetic patients, and hopefully for a single patient. This appears consistent with the expected future for the care of diabetes (thus including diabetic foot care), moving towards precision and even personalized (i.e., for the single individual) medicine [ 92 , 93 , 94 , 95 , 96 ]. In fact, the integration of different sensing strategies, which is advisable for the reasons explained (mainly, the heterogeneity of diabetic foot syndrome), coupled with appropriate artificial intelligence approaches (able to “evolve” and improve their performances), offers important grounds for the application of concepts in the context of precision and personalized medicine.…”

Chemical Compounds and Ambient Factors Affecting Pancreatic Alpha-Cells Mass and Function: What Evidence?

“…However, we believe that the potential relevance is remarkable, at least considered in perspective, for the near future. Indeed, there has recently been a vigorous move towards precision medicine in diabetes, including precision diagnostics [ 116 , 117 , 118 , 119 , 120 , 121 , 122 ]. Thus, we expect that soon it may become part of the clinical routine for assessing the specific metabolic defects of a patient with diabetes, or even simple prediabetes or dysglycemia.…”

A Strategic Research Framework for Defeating Diabetes in India: A 21st-Century Agenda

“…The emerging question of diabetes phenotypes, and resulting implications for precision medicine and public health, is of great topical interest worldwide. 10 Well-conducted research in Indian populations—in which some phenotypes are more widely prevalent and novel phenotypes may manifest—can provide ground-breaking and widely generalizable findings with global impact. 11 Yet, gradients in risk of complications across phenotypes as the diabetes epidemic evolves, coupled with the vast population diversity, offer contextual opportunities to explore important questions regarding gene–environment interactions in diabetes causation and in the differences manifest in disease phenotypes and pathophysiology.…”